Etoricoxib Contraindications in End-Stage Renal Disease

Introduction to Etoricoxib Risks

• The American Heart Association recommends avoiding etoricoxib and all NSAIDs, including COX-2 selective inhibitors, in patients with end-stage renal disease due to significant risks of cardiovascular toxicity, fluid retention, heart failure exacerbation, and gastrointestinal bleeding that outweigh any analgesic benefits 1

Cardiovascular and Renal Risks

• The American College of Cardiology notes that NSAIDs impair renal function in patients with decreased effective circulating volume and promote sodium and water retention, directly increasing the risk of heart failure hospitalization 1
• The American Thoracic Society warns that NSAIDs substantially elevate bleeding risk, particularly when combined with other medications commonly used in ESRD patients 2, 3

Pain Management Alternatives

• The American Academy of Pain Medicine recommends acetaminophen (paracetamol) as the preferred first-line analgesic, safe at standard doses up to 4 grams per 24 hours 4
• The American Society of Health-System Pharmacists suggests that primary concern is hepatic toxicity (not renal), making acetaminophen far safer than NSAIDs 4

Opioid Use in ESRD

• The American Pain Society recommends preferred opioids (in order of safety) for severe pain: methadone, fentanyl, and buprenorphine, as they have no active metabolites 4
• The National Kidney Foundation advises using oxycodone and hydromorphone with caution and dose reduction, and avoiding morphine, codeine, meperidine, and tramadol due to toxic metabolite accumulation 4

Neuropathic Pain Management

• The American Heart Association recommends using SSRIs instead of SNRIs in ESRD patients with cardiovascular disease, as SNRIs can cause hypertension at high doses 1
• The American College of Cardiology notes that gabapentin and pregabalin require renal dose adjustment and carry risks of fluid retention and heart failure exacerbation 1

Critical Pitfalls to Avoid

• The American College of Cardiology warns to never use NSAIDs for routine pain management in ESRD, regardless of COX-2 selectivity 1
• The American Thoracic Society advises avoiding combining antiplatelet therapy (including low-dose aspirin) with any NSAID in ESRD patients, as this substantially elevates bleeding risk 2, 3

Monitoring Requirements

• The American Heart Association recommends monitoring blood pressure closely for worsening hypertension if NSAIDs are absolutely unavoidable 1
• The American College of Cardiology suggests assessing for signs of fluid retention and heart failure exacerbation, and checking for gastrointestinal bleeding symptoms if NSAIDs are used 1